<?xml version="1.0" encoding="UTF-8"?>
<p>Although curcumin is safe and efficacious, it is not an approved therapeutic agent because of its low bioavailability, poor aqueous solubility, and complications with drug delivery, which are challenges that have yet to be overcome [
 <xref rid="B94-molecules-25-02796" ref-type="bibr">94</xref>,
 <xref rid="B116-molecules-25-02796" ref-type="bibr">116</xref>]. To improve upon curcumin’s stability at plasma pH, Balasubramanian and co-workers (2019) generated four synthetic monoketone analogues of curcumin (curcuminoids) and tested them for their anti-DENV activity [
 <xref rid="B97-molecules-25-02796" ref-type="bibr">97</xref>]. Three out of four synthetic curcuminoids—namely the acyclic, cyclopentanone, and cyclohexanone analogues of curcumin—were shown to possess better antiviral activities with improved stability as compared to native curcumin [
 <xref rid="B97-molecules-25-02796" ref-type="bibr">97</xref>]. Modifications upon the chemical structure is one of the many strategies than can be employed to improve upon the bioavailability of curcumin [
 <xref rid="B116-molecules-25-02796" ref-type="bibr">116</xref>].
</p>
